Activating PPAR‐γ by other agonists has been frequently examined to treat oxidative stress‐related diseases such as diabetes (Chan et al., 2010; Kleinhenz et al., 2009; Yousefipour et al., 2010) and some brain disease such as AD and Parkinson's disease (Hunter & Bing, 2007; Lee et al., 2010). The gene discussed is PPARG; the disease is brain disorder.